Addressing the Risks of Chemo-Induced Myelosuppression in SCLC


Trilaciclib and the Economic Value of Multilineage Myeloprotection From Chemo-Induced Myelosuppression in ES-SCLC Treated With 1L Chemo

639 views
June 6, 2022
Comments 0
Login to view comments. Click here to Login